Doxorubicin and paclitaxel carried by methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) is superior than traditional drug-delivery methods

Yili Hu; Xiaoyang Zhu; Ruifang Zhao; Jin Wang; Yipeng Song; Guangjun Nie; Huiru Tang; Yulan Wang

doi:10.2217/nnm-2017-0363

Doxorubicin and paclitaxel carried by methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) is superior than traditional drug-delivery methods

Yili Hu, Xiaoyang Zhu, Ruifang Zhao, Jin Wang, Yipeng Song, Guangjun Nie, Huiru Tang, Yulan Wang

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Aim: To evaluate the advantages of nanomaterial methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) encapsulated doxorubicin (D/DOX) and paclitaxel (T/TAX; mPEG-PLGA-DT) over free form of DOX and TAX (DOX/TAX). Materials & methods: Metabonomics was conducted to characterize the systemic metabolic response of allograft breast cancer model mice to mPEG-PLGA-DT and DOX/TAX treatments. Results: Breast tumor growth induced metabolic reprogram in serum and multiple organs. DOX/TAX treatment could ameliorate the elevated energy and nucleotides demands in some organs while mPEG-PLGA-DT treatment showed outstanding therapeutic outcomes in restoring the metabolic phenotypes of serum and kidney from tumor-bearing mice to the healthy state. Conclusion: This investigation proved the biological advantages of mPEG-PLGA-DT over DOX/TAX in molecular level through the comparison between their metabolic responses in vivo.

Original language	English (US)
Pages (from-to)	913-928
Number of pages	16
Journal	Nanomedicine
Volume	13
Issue number	8
DOIs	https://doi.org/10.2217/nnm-2017-0363
State	Published - Apr 2018

Keywords

Anticancer drugs
Biomedical applications
Metabonomics
NMR
Nuclear magnetic resonance
Polymer nanoparticles

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
Materials Science(all)

Access to Document

10.2217/nnm-2017-0363

Cite this

@article{be501822e1d040f693263aa67dfe0998,

title = "Doxorubicin and paclitaxel carried by methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) is superior than traditional drug-delivery methods",

abstract = "Aim: To evaluate the advantages of nanomaterial methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) encapsulated doxorubicin (D/DOX) and paclitaxel (T/TAX; mPEG-PLGA-DT) over free form of DOX and TAX (DOX/TAX). Materials & methods: Metabonomics was conducted to characterize the systemic metabolic response of allograft breast cancer model mice to mPEG-PLGA-DT and DOX/TAX treatments. Results: Breast tumor growth induced metabolic reprogram in serum and multiple organs. DOX/TAX treatment could ameliorate the elevated energy and nucleotides demands in some organs while mPEG-PLGA-DT treatment showed outstanding therapeutic outcomes in restoring the metabolic phenotypes of serum and kidney from tumor-bearing mice to the healthy state. Conclusion: This investigation proved the biological advantages of mPEG-PLGA-DT over DOX/TAX in molecular level through the comparison between their metabolic responses in vivo.",

keywords = "Anticancer drugs, Biomedical applications, Metabonomics, NMR, Nuclear magnetic resonance, Polymer nanoparticles",

author = "Yili Hu and Xiaoyang Zhu and Ruifang Zhao and Jin Wang and Yipeng Song and Guangjun Nie and Huiru Tang and Yulan Wang",

note = "Funding Information: This work was supported by the National Natural Science Foundation of China (21675169, 21375144, 91439102 and 81590953) and Ministry of Science and Technology 973 (2017YFC0906800, 2012CB934004). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2018 Future Medicine Ltd.",

year = "2018",

month = apr,

doi = "10.2217/nnm-2017-0363",

language = "English (US)",

volume = "13",

pages = "913--928",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "8",

}

TY - JOUR

T1 - Doxorubicin and paclitaxel carried by methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) is superior than traditional drug-delivery methods

AU - Hu, Yili

AU - Zhu, Xiaoyang

AU - Zhao, Ruifang

AU - Wang, Jin

AU - Song, Yipeng

AU - Nie, Guangjun

AU - Tang, Huiru

AU - Wang, Yulan

N1 - Funding Information: This work was supported by the National Natural Science Foundation of China (21675169, 21375144, 91439102 and 81590953) and Ministry of Science and Technology 973 (2017YFC0906800, 2012CB934004). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2018 Future Medicine Ltd.

PY - 2018/4

Y1 - 2018/4

N2 - Aim: To evaluate the advantages of nanomaterial methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) encapsulated doxorubicin (D/DOX) and paclitaxel (T/TAX; mPEG-PLGA-DT) over free form of DOX and TAX (DOX/TAX). Materials & methods: Metabonomics was conducted to characterize the systemic metabolic response of allograft breast cancer model mice to mPEG-PLGA-DT and DOX/TAX treatments. Results: Breast tumor growth induced metabolic reprogram in serum and multiple organs. DOX/TAX treatment could ameliorate the elevated energy and nucleotides demands in some organs while mPEG-PLGA-DT treatment showed outstanding therapeutic outcomes in restoring the metabolic phenotypes of serum and kidney from tumor-bearing mice to the healthy state. Conclusion: This investigation proved the biological advantages of mPEG-PLGA-DT over DOX/TAX in molecular level through the comparison between their metabolic responses in vivo.

AB - Aim: To evaluate the advantages of nanomaterial methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) encapsulated doxorubicin (D/DOX) and paclitaxel (T/TAX; mPEG-PLGA-DT) over free form of DOX and TAX (DOX/TAX). Materials & methods: Metabonomics was conducted to characterize the systemic metabolic response of allograft breast cancer model mice to mPEG-PLGA-DT and DOX/TAX treatments. Results: Breast tumor growth induced metabolic reprogram in serum and multiple organs. DOX/TAX treatment could ameliorate the elevated energy and nucleotides demands in some organs while mPEG-PLGA-DT treatment showed outstanding therapeutic outcomes in restoring the metabolic phenotypes of serum and kidney from tumor-bearing mice to the healthy state. Conclusion: This investigation proved the biological advantages of mPEG-PLGA-DT over DOX/TAX in molecular level through the comparison between their metabolic responses in vivo.

KW - Anticancer drugs

KW - Biomedical applications

KW - Metabonomics

KW - NMR

KW - Nuclear magnetic resonance

KW - Polymer nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85047516484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047516484&partnerID=8YFLogxK

U2 - 10.2217/nnm-2017-0363

DO - 10.2217/nnm-2017-0363

M3 - Article

C2 - 29527969

AN - SCOPUS:85047516484

VL - 13

SP - 913

EP - 928

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 8

ER -

Doxorubicin and paclitaxel carried by methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) is superior than traditional drug-delivery methods

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this